Connect with us
Wise usd campaign
ADVERTISEMENT

China

Is Australia’s trade war with China now over? The answer might be out of our hands

Published

on

Australia’s rock lobster industry can export to China again, ending a significant trade barrier. However, future relations depend on geopolitical dynamics between China and the U.S., warranting cautious optimism.

Finally, Australia’s rock lobster industry will be able to export to China again, following a deal struck on the sidelines of the ASEAN summit in Laos last week.

It will take some weeks to finalise the paperwork, but Chinese diners can expect to eat our high-quality crustaceans as we devour our Christmas roast turkeys.

The breakthrough brings a particularly nasty chapter in Australia-China trade relations to a close. Tariffs on rock lobsters were the only remaining major restriction of a raft of trade barriers imposed by China in 2020.

It might be tempting to celebrate, but we should tread carefully. Our situation remains hostage to Beijing’s relationship with Washington. Whether Australia’s trade woes with China are actually over may ultimately be out of our hands.

Read more:
China removes block on Australian lobster, in last big bilateral trade breakthrough

Australia’s reversal of fortunes

The past couple of years have been a whirlwind.

The Albanese government has seen China systematically undo the export restrictions it had imposed on Australia in 2020 – including on barley, wine, beef, and now lobster – without giving away much of substance in return.

Yes, Australia suspended two cases it had brought against China at the World Trade Organization, concerning barley and wine duties China had imposed. But those cases can be resumed if the Chinese government backslides.

China will resume imports of Australian lobster by the end of this year.
Abdul Razak Latif/Shutterstock

And true, the Albanese government did not oppose China’s bid to join the Comprehensive and Progressive Agreement for Trans-Pacific Partnership – an important regional free trade agreement of which Australia is a founding member. But neither did it endorse China’s bid.

It seems we’ve come a long way since 2020, when China tabled its infamous “14 grievances” against Australia. This deliberately leaked document publicly criticised Australia on a whole range of fronts, including foreign investment decisions, alleged interference in China’s affairs, research funding and media coverage.

A more sobering picture elsewhere

This reopening of trade might make it seem like things are looking up for Australia. In some cases, our business community has bounced back with gusto, notably wine exports to China.

Zooming out, however, paints a more sobering picture of global trade relations. In the near term, the decisions of our key allies – namely the United States – may come to matter more than our own.

The Biden administration has long hoped to place a “floor” under America’s geopolitical competition with China. Neither side wants things to get ugly.

But in Washington, strong bipartisan consensus remains that China must be confronted. The US has continued to take coercive actions against Chinese exports and investment.

For example, the US recently imposed a 100% import duty on electric vehicles produced by Chinese-owned companies. Similarly, it imposed a 25% import duty on imports of Chinese container cranes. Strategic distrust will escalate no matter who wins the White House on November 5.

This animosity is mirrored in Beijing. China’s security state is expanding ever more into business, while its private sector retreats. China’s own coercive activities are also escalating in regional disputes over the South and East China seas, as well as in its trade retaliations against Western markets.

Distrust continues to simmer between China and the US.
Doug Mills/The New York Times via AP, Pool

Widening tensions

These tensions are also playing out in Europe and the Middle East. International relations scholars worry that the West must now confront an authoritarian axis comprising Russia, Iran, North Korea and China.

China’s “no limits” partnership with Russia has spooked most European elites. Western sanctions on Russia, meant to erode the Kremlin’s war machine, are likely being circumvented by China’s unmatched industrial capacities.

Iran’s military support for Russia supplements the Kremlin’s war-fighting capacities at Ukraine’s expense.

Unsurprisingly, economic security concerns are rapidly eclipsing free trade considerations for the US.

Advanced manufacturing capabilities – such as semiconductor production – are increasingly important strategic assets.
genkur/Shutterstock

When US National Security Advisor Jake Sullivan introduced the 2022 National Security Strategy, he adopted a selectively restrictive approach he called “small yard, high fence”.

He was talking about export controls and inward restrictions on investment, applied to high-technology products.

Since then, the “yard” has grown wider, and the “fence” has expanded. More sectors and products are being thrown into the mix, from energy security, through critical minerals, to food production.

The challenge with digital technologies, able to be used for both military and civilian purposes, is that the yard can be very large indeed.

Middle power problems

The US has the economic and military weight to confront China. As the European Union is learning, having the economic weight is necessary. But being politically united is essential, and they remain far from that.

Australia is a middle power, without the necessary economic weight or military heft to confront China. That means we must support the rules-based multilateral trading system – preserving the authority of institutions like the World Trade Organisation (WTO) – to constrain the actions of the great powers and preserve as much of our open trade posture as possible.

Australian Prime Minister Anthony Albanese attended the ASEAN Summit in Laos last week.
Rungroj Yongrit/EPA

Washington, however, increasingly expects its allies to fall into line. How else can one explain Canada’s decision to follow the US and impose 100% import duties on electric vehicles produced by Chinese owned companies?

Like Australia, Canada is also a middle power. It is also a strong supporter of the rules-based multilateral trading system. But Canada’s action violates WTO rules.

The fact that Washington’s actions also violate these rules is taken for granted these days.

Australia must pay attention

Global trade cooperation is deteriorating, and the world is fracturing into two “values-based” trading blocs. While there could be positive upswings in our bilateral trade relations with China, the medium term trend is down.

As Napoleon Bonaparte is reputed to have said:

China is a sleeping giant; let him sleep, for if he wakes he will shake the world.

China has changed, and the world with it.

Australian business needs to pay attention. Our East Asian partners, notably Japan and South Korea, have long spoken of the need for a “China plus one” (or more) business strategy – making sure trade and investment is diversified into other countries, as well.

Such diversification will be increasingly important in the years to come.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Business

Wegovy: The Popular Weight-Loss Drug Now Available in China

Published

on

Novo Nordisk launched Wegovy in China after approval, competing with Eli Lilly’s upcoming weight-loss drug. The treatment, costing 1,400 yuan, targets obesity but has potential side effects and isn’t covered by healthcare.


Wegovy Launch in China

Novo Nordisk recently launched its weight-loss drug, Wegovy, in China after obtaining approval from local health authorities in June. The introduction of Wegovy is expected to increase competition with Eli Lilly, which has also received approval for its weight-loss treatment, although it has not yet been released in China’s significant pharmaceutical market.

Cost and Accessibility

In China, a set of four Wegovy injections will be priced at 1,400 yuan (approximately $194), significantly lower than the drug’s U.S. price. However, patients will need to pay the full amount out of pocket since Wegovy is not yet covered by the national healthcare insurance plan.

Benefits and Side Effects

Research indicates that Wegovy can help users lose over 10% of their body weight. The drug contains semaglutide, which assists with appetite control and satiety. While Wegovy has been gaining traction globally, it may cause side effects like nausea. Concerns have emerged about its misuse among individuals who are not obese, prompting medical professionals to remain vigilant.

Source : Popular weight-loss drug Wegovy goes on sale in China

Continue Reading

China

China Implements New Measures to Increase Foreign Investment in A-Share Market

Published

on

China’s 2024 updates to strategic investment rules simplify A-share market access for foreign investors by lowering shareholding thresholds, reducing lock-up periods, and increasing investment options, reflecting a commitment to greater market openness and participation in economic reform.


The 2024 updates to China’s strategic investment rules simplify entry for foreign investors in the A-share market by lowering shareholding thresholds, reducing lock-up periods, and expanding investment options, signaling a commitment to increased market openness and flexibility through these new measures.

China’s capital markets are undergoing a significant transformation as part of the nation’s ongoing commitment to economic reform and openness. The recent update to the Administrative Measures for Strategic Investment in Listed Companies by Foreign Investors (hereinafter, the “new measures”) reflects this commitment, targeting an increase in foreign investor participation in China’s A-share market. For nearly two decades, China’s “strategic investment” pathway provided foreign investors with access to shares in A-share listed companies, but strict requirements—such as high minimum investment thresholds and prolonged lock-up periods—made it accessible only to select large investors.

The new measures, effective December 2, 2024, relax many of these restrictions to attract a broader and more diverse range of foreign investors. Key changes include lowering the minimum shareholding threshold from 10 percent to 5 percent, reducing the asset requirements from US$100 million to US$50 million in assets, and shortening the lock-up period from three years to one. Additionally, foreign investors can now use equity from unlisted overseas companies as consideration, while new investment routes, like tender offers, enhance flexibility.

In 2005, China introduced the Strategic Investment Regime as part of its broader efforts to open up its financial markets to foreign capital while retaining a level of control over sensitive industries. This framework allowed qualified foreign investors to acquire strategic stakes in Chinese A-share listed companies, aiming to promote foreign participation in the domestic market.

However, the stringent requirements—such as high minimum investment thresholds and extended lock-up periods—restricted this pathway to a limited pool of large, multinational investors. The regime reflected China’s cautious approach at the time, seeking to balance openness with economic stability and control over critical sectors.

A decade later, in 2015, China implemented its first significant revisions to the Strategic Investment Regime. These amendments sought to make the investment process more accessible by easing certain restrictions, aiming to encourage foreign capital inflow as China continued its gradual integration into global markets.

While some requirements were relaxed, the fundamental limitations—such as high entry thresholds and complex approval processes—remained in place, meaning that access to China’s A-share market was still primarily confined to major institutional investors with substantial capital.


This article was first published by China Briefing , which is produced by Dezan Shira & Associates. The firm assists foreign investors throughout Asia from offices across the world, including in in ChinaHong KongVietnamSingapore, and India . Readers may write to info@dezshira.com for more support.

Read the rest of the original article.

Continue Reading

China

Less is More: Rethinking Indonesia’s Tariffs on China

Published

on

Rising concerns over China’s industrial overcapacity have led countries to impose higher tariffs, including Indonesia’s planned 200% tariffs on Chinese goods, risking Indonesia’s competitiveness and economic security.


Tariffs Escalate Amid Concerns of Overcapacity

Concerns regarding China’s industrial overcapacity have prompted countries to increase tariffs on Chinese goods. Indonesia, following the U.S. example, plans to impose tariffs as high as 200 percent on various Chinese imports, including textiles and ceramics. This response aims to safeguard local jobs from the influx of inexpensive Chinese products.

Economic Impact of Tariffs

These tariffs are designed as safeguards and anti-dumping measures against potential job losses in Indonesia. However, the ongoing investigations have not definitively shown that China’s practices are the root cause of these issues. The political appeal of broad tariffs might lead to unintended consequences, such as reducing the overall competitiveness of Indonesian exports and risking retaliatory measures from affected countries.

Dependency on Chinese Goods

Indonesia heavily relies on Chinese manufacturing inputs, which constituted over 26 percent of its intermediary goods imports in 2021. With competitive pricing, these inputs have enhanced Indonesia’s export capabilities, particularly to markets like the U.S., where the trade surplus increased from $8.58 billion in 2019 to $11.96 billion in 2023. Reducing trade openness may ultimately undermine the Indonesian economy’s resilience against geopolitical challenges.

Source : Less is more for Indonesia’s tariffs on China

Source link

Continue Reading